Needham & Company LLC Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $22.00

Stoke Therapeutics (NASDAQ:STOK) had its price target boosted by Needham & Company LLC from $14.00 to $22.00 in a research note released on Tuesday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other brokerages have also weighed in on STOK. TD Cowen raised Stoke Therapeutics from a market perform rating to an outperform rating in a report on Tuesday. JPMorgan Chase & Co. upped their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a neutral rating in a report on Tuesday. HC Wainwright reaffirmed a buy rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Finally, Canaccord Genuity Group upped their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a buy rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of Moderate Buy and an average target price of $19.63.

Stoke Therapeutics Trading Down 4.7 %

Shares of Stoke Therapeutics stock opened at $13.50 on Tuesday. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40. The stock has a market capitalization of $625.05 million, a P/E ratio of -5.70 and a beta of 0.68. The business’s fifty day moving average price is $6.24 and its 200 day moving average price is $5.08.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the transaction, the insider now owns 6,981 shares of the company’s stock, valued at $33,508.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. Insiders sold 37,615 shares of company stock worth $212,852 over the last ninety days. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of STOK. Swiss National Bank increased its holdings in shares of Stoke Therapeutics by 8.2% in the first quarter. Swiss National Bank now owns 30,500 shares of the company’s stock valued at $642,000 after buying an additional 2,300 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Stoke Therapeutics by 20.8% in the first quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company’s stock valued at $412,000 after buying an additional 3,374 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Stoke Therapeutics by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after buying an additional 837 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Stoke Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 11,621 shares of the company’s stock valued at $245,000 after buying an additional 4,289 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Stoke Therapeutics by 7.6% in the first quarter. Rhumbline Advisers now owns 19,345 shares of the company’s stock valued at $407,000 after buying an additional 1,362 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.